The Medicines Company Company Profile (NASDAQ:MDCO)

About The Medicines Company (NASDAQ:MDCO)

The Medicines Company logoThe Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Generic Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:MDCO
  • CUSIP: 58468810
  • Web:
  • Market Cap: $2.70626 billion
  • Outstanding Shares: 71,072,000
Average Prices:
  • 50 Day Moving Avg: $41.97
  • 200 Day Moving Avg: $44.06
  • 52 Week Range: $30.80 - $55.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.44
  • P/E Growth: -0.09
Sales & Book Value:
  • Annual Revenue: $141.74 million
  • Price / Sales: 19.47
  • Book Value: $7.26 per share
  • Price / Book: 5.35
  • EBIDTA: ($306,000,000.00)
  • Net Margins: -91.25%
  • Return on Equity: -19.09%
  • Return on Assets: -7.60%
  • Debt-to-Equity Ratio: 0.59%
  • Current Ratio: 1.04%
  • Quick Ratio: 0.90%
  • Average Volume: 1.37 million shs.
  • Beta: 0.85
  • Short Ratio: 11.11

Frequently Asked Questions for The Medicines Company (NASDAQ:MDCO)

What is The Medicines Company's stock symbol?

The Medicines Company trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines Company's earnings last quarter?

The Medicines Company (NASDAQ:MDCO) released its earnings results on Wednesday, April, 26th. The company reported ($1.44) earnings per share for the quarter, missing analysts' consensus estimates of ($1.13) by $0.31. The business earned $24.20 million during the quarter, compared to analysts' expectations of $37.76 million. The Medicines Company had a negative return on equity of 19.09% and a negative net margin of 91.25%. The business's revenue for the quarter was down 51.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.03) EPS. View The Medicines Company's Earnings History.

Where is The Medicines Company's stock going? Where will The Medicines Company's stock price be in 2017?

11 brokerages have issued 1-year target prices for The Medicines Company's stock. Their predictions range from $50.00 to $65.00. On average, they anticipate The Medicines Company's stock price to reach $56.11 in the next year. View Analyst Ratings for The Medicines Company.

What are analysts saying about The Medicines Company stock?

Here are some recent quotes from research analysts about The Medicines Company stock:

  • 1. Jefferies Group LLC analysts commented, " ACC (Mar 17-19) will be a key meeting for inclisiran, where MDCO will detail full 6-mo data for ORION-1 and AMGN will present the FOURIER data. Data from the latter should help guide PIII development for inclisiran, for which MDCO continues to seek a partner. On positive FOURIER results, we lower our risk-discount on inclisiran and our PT increases to $62 (v. $49 prev)." (3/1/2017)
  • 2. According to Zacks Investment Research, "The Medicines Co. has two potential blockbusters, Inclisiran and Carbavance, in different stages of development. Moreover, divestment of non-core assets to drive shareholder value is encouraging. We are also encouraged by the company’s acquisitions and in-licensing agreements to grow its pipeline. Moreover, the company’s shares have outperformed the Zacks classified Medical-Biomedical/Genetics industry in last one year. However the company is facing generic competition for its flagship product, Angiomax. With Angiomax sales eroding due to the presence of generics, the company’s ability to successfully develop and bring new products to market is important for future growth and any regulatory setbacks would weigh heavily on the stock. Estimates have been stable lately ahead of the company’s Q4 earnings release. The company has positive record of earnings surprises in recent quarters." (1/10/2017)

Who are some of The Medicines Company's key competitors?

Who are The Medicines Company's key executives?

The Medicines Company's management team includes the folowing people:

  • Stuart A. Kingsley, President, Chief Operating Officer
  • Clive A. Meanwell M.D. Ph.D., Chief Executive Officer, Director
  • William Bernard O'Connor, Chief Financial Officer
  • Christopher T. Cox, Executive Vice President, Chief Corporate Development Officer
  • Jeffrey Frazier, Executive Vice President, Chief Human Strategy Officer
  • Stephen M. Rodin J.D., General Counsel, Secretary
  • Fredric N. Eshelman, Independent Non-Executive Chairman of the Board
  • Paris Panayiotopoulos, Director
  • William W. Crouse, Independent Director
  • Alexander J. Denner Ph.D., Independent Director

Who owns The Medicines Company stock?

The Medicines Company's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.16%), Vanguard Group Inc. (8.62%), Aviva Holdings Ltd. (5.39%), Iridian Asset Management LLC CT (4.28%), State Street Corp (2.87%) and Sarissa Capital Management LP (2.47%). Company insiders that own The Medicines Company stock include Armin M Kessler, Christopher T Cox, Clive Meanwell, Elizabeth H S Wyatt, Fredric N Eshelman, Glenn Sblendorio, Hiroaki Shigeta, Melvin K Spigelman, Robert G Savage, William Bernard O'connor and William Crouse. View Institutional Ownership Trends for The Medicines Company.

Who sold The Medicines Company stock? Who is selling The Medicines Company stock?

The Medicines Company's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Broadfin Capital LLC, Ashford Capital Management Inc., Nationwide Fund Advisors, Signpost Capital Advisors LP, Alliancebernstein L.P., Teachers Retirement System of The State of Kentucky and SG Americas Securities LLC. Company insiders that have sold The Medicines Company stock in the last year include Clive Meanwell, Hiroaki Shigeta and William Bernard O'connor. View Insider Buying and Selling for The Medicines Company.

Who bought The Medicines Company stock? Who is buying The Medicines Company stock?

The Medicines Company's stock was acquired by a variety of institutional investors in the last quarter, including Aviva Holdings Ltd., Iridian Asset Management LLC CT, Blue Ridge Capital L.L.C., Frontier Capital Management Co. LLC, Vanguard Group Inc., Westfield Capital Management Co. LP, Elk Creek Partners LLC and Ameriprise Financial Inc.. Company insiders that have bought The Medicines Company stock in the last two years include Christopher T Cox and Fredric N Eshelman. View Insider Buying and Selling for The Medicines Company.

How do I buy The Medicines Company stock?

Shares of The Medicines Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is The Medicines Company's stock price today?

One share of The Medicines Company stock can currently be purchased for approximately $38.83.

MarketBeat Community Rating for The Medicines Company (NASDAQ MDCO)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  425
MarketBeat's community ratings are surveys of what our community members think about The Medicines Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for The Medicines Company (NASDAQ:MDCO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $56.11 (44.50% upside)

Analysts' Ratings History for The Medicines Company (NASDAQ:MDCO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/23/2017CIBCSet Price Target$50.00MediumView Rating Details
5/22/2017Oppenheimer Holdings, Inc.Initiated CoverageMarket Perform$50.00LowView Rating Details
4/19/2017Cowen and CompanyBoost Price TargetOutperform$39.00 -> $61.00LowView Rating Details
4/12/2017Jefferies Group LLCReiterated RatingBuy$62.00LowView Rating Details
3/20/2017HC WainwrightReiterated RatingBuy$60.00HighView Rating Details
3/18/2017J P Morgan Chase & CoReiterated RatingBuyHighView Rating Details
3/1/2017Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
1/8/2017Chardan CapitalReiterated RatingBuy$65.00N/AView Rating Details
11/18/2016GuggenheimReiterated RatingBuyN/AView Rating Details
11/8/2016Leerink SwannReiterated RatingOutperform$53.00 -> $50.00N/AView Rating Details
8/2/2016Citigroup Inc.Reiterated RatingHoldN/AView Rating Details
7/12/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
11/6/2015Piper Jaffray CompaniesReiterated RatingNeutral$28.00 -> $31.00N/AView Rating Details
7/6/2015MizuhoUpgradeNeutral -> Buy$28.00 -> $41.00N/AView Rating Details
(Data available from 6/22/2015 forward)


Earnings History for The Medicines Company (NASDAQ:MDCO)
Earnings by Quarter for The Medicines Company (NASDAQ:MDCO)
Earnings History by Quarter for The Medicines Company (NASDAQ MDCO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017Q1 2017($1.13)($1.44)$37.76 million$24.20 millionViewN/AView Earnings Details
2/28/2017Q416($1.43)($1.29)$26.91 million$25.20 millionViewListenView Earnings Details
10/26/2016Q316($1.38)($0.64)$37.26 million$37.60 millionViewListenView Earnings Details
7/27/2016Q216($1.16)($0.62)$41.93 million$54.70 millionViewListenView Earnings Details
5/9/2016Q116($0.89)($1.03)$48.96 million$50.30 millionViewListenView Earnings Details
2/17/2016Q415($1.54)($0.88)$64.11 million$67.20 millionViewN/AView Earnings Details
11/3/2015Q315($0.88)($0.90)$68.58 million$72.70 millionViewListenView Earnings Details
7/29/2015Q215($0.20)($0.74)$122.58 million$90.50 millionViewListenView Earnings Details
5/5/2015Q115($0.68)($0.02)$138.78 million$126.50 millionViewListenView Earnings Details
2/18/2015Q414($0.84)$0.11$188.55 million$191.00 millionViewListenView Earnings Details
10/22/2014Q314($0.10)$0.10$188.30 million$172.40 millionViewListenView Earnings Details
7/23/2014Q214($0.07)$0.22$183.75 million$183.80 millionViewListenView Earnings Details
4/23/2014Q114($0.13)$0.22$175.60 million$177.20 millionViewListenView Earnings Details
2/19/2014Q413$0.11$0.26$182.60 million$185.00 millionViewListenView Earnings Details
10/23/2013Q313$0.24$0.47$173.86 million$173.45 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.33$0.50$168.70 million$172.00 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.26)$0.31$152.63 million$155.80 millionViewListenView Earnings Details
2/20/2013Q4 2012$0.28$0.38$146.09 million$159.50 millionViewListenView Earnings Details
10/24/2012$0.39$0.40ViewN/AView Earnings Details
7/25/2012$0.22$0.46ViewN/AView Earnings Details
4/25/2012$0.14$0.27ViewN/AView Earnings Details
2/22/2012$0.24$0.52ViewN/AView Earnings Details
10/26/2011$0.20$0.17ViewN/AView Earnings Details
7/27/2011$0.31$0.21ViewN/AView Earnings Details
4/27/2011$0.40$0.45ViewN/AView Earnings Details
2/16/2011$0.24$0.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for The Medicines Company (NASDAQ:MDCO)
2017 EPS Consensus Estimate: ($5.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.36)($1.06)($1.21)
Q2 20173($1.40)($1.10)($1.23)
Q3 20173($1.70)($1.17)($1.51)
Q4 20173($1.36)($0.97)($1.15)
(Data provided by Zacks Investment Research)


Dividend History for The Medicines Company (NASDAQ:MDCO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for The Medicines Company (NASDAQ:MDCO)
Insider Ownership Percentage: 7.90%
Insider Trades by Quarter for The Medicines Company (NASDAQ:MDCO)
Institutional Ownership by Quarter for The Medicines Company (NASDAQ:MDCO)
Insider Trades by Quarter for The Medicines Company (NASDAQ:MDCO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017William Bernard O'connorCFOSell25,833$46.20$1,193,484.60View SEC Filing  
12/8/2016Christopher T CoxEVPBuy105,500$33.20$3,502,600.00View SEC Filing  
12/8/2016Fredric N EshelmanDirectorBuy621,720$33.77$20,995,484.40View SEC Filing  
9/21/2016Clive MeanwellCEOSell8,623$40.00$344,920.00View SEC Filing  
9/1/2016Clive MeanwellCEOSell1,377$40.00$55,080.00View SEC Filing  
8/24/2016Clive MeanwellCEOSell20,000$40.00$800,000.00View SEC Filing  
7/11/2016Hiroaki ShigetaDirectorSell3,849$38.50$148,186.50View SEC Filing  
6/10/2016Christopher T CoxEVPBuy45,985$37.90$1,742,831.50View SEC Filing  
6/7/2016Christopher T CoxEVPBuy53,340$37.55$2,002,917.00View SEC Filing  
5/24/2016Melvin K SpigelmanDirectorSell15,000$37.00$555,000.00View SEC Filing  
5/16/2016Clive MeanwellCEOSell10,000$35.00$350,000.00View SEC Filing  
5/16/2016William CrouseDirectorSell15,000$35.15$527,250.00View SEC Filing  
5/13/2016Elizabeth H S WyattDirectorSell15,000$34.07$511,050.00View SEC Filing  
5/12/2016Fredric N EshelmanDirectorBuy300,000$33.68$10,104,000.00View SEC Filing  
3/7/2016Armin M KesslerDirectorSell8,100$34.82$282,042.00View SEC Filing  
11/13/2015Robert G. SavageDirectorSell5,000$39.34$196,700.00View SEC Filing  
9/3/2015Glenn SblendorioCFOSell25,000$42.00$1,050,000.00View SEC Filing  
8/31/2015Clive MeanwellCEOSell49,998$39.36$1,967,921.28View SEC Filing  
8/31/2015Glenn SblendorioCFOSell114,495$39.75$4,551,176.25View SEC Filing  
8/31/2015Melvin K. SpigelmanDirectorSell20,000$40.50$810,000.00View SEC Filing  
8/31/2015William Bernard O'connorSVPSell35,451$40.00$1,418,040.00View SEC Filing  
7/1/2015Clive MeanwellCEOSell16,667$28.39$473,176.13View SEC Filing  
6/25/2015Glenn SblendorioCFOSell3,305$32.00$105,760.00View SEC Filing  
6/8/2015Hiroaki ShigetaDirectorSell7,500$28.99$217,425.00View SEC Filing  
5/20/2015Robert G SavageDirectorSell15,000$26.78$401,700.00View SEC Filing  
4/16/2015William Bernard O'connorSVPSell1,281$30.00$38,430.00View SEC Filing  
4/1/2015Clive MeanwellCEOSell16,667$27.58$459,675.86View SEC Filing  
3/30/2015Elizabeth H S WyattDirectorSell20,000$28.08$561,600.00View SEC Filing  
3/23/2015Clive MeanwellCEOSell16,667$30.62$510,343.54View SEC Filing  
3/23/2015Glenn SblendorioCFOSell34,773$30.78$1,070,312.94View SEC Filing  
3/2/2015William Bernard O'connorSVPSell2,988$28.78$85,994.64View SEC Filing  
3/3/2014William Bernard O'connorSVPSell2,968$30.31$89,960.08View SEC Filing  
1/21/2014Paul Michael AntinoriVPSell37,883$38.02$1,440,311.66View SEC Filing  
1/15/2014William Bernard O'connorSVPSell4,427$39.15$173,317.05View SEC Filing  
1/10/2014William Bernard O'connorSVPSell72,384$40.00$2,895,360.00View SEC Filing  
1/7/2014Clive MeanwellCEOSell27,929$38.13$1,064,932.77View SEC Filing  
1/3/2014Clive MeanwellCEOSell57,516$38.16$2,194,810.56View SEC Filing  
12/9/2013William CrouseDirectorSell12,500$38.00$475,000.00View SEC Filing  
12/5/2013Glenn SblendorioCFOSell8,516$38.50$327,866.00View SEC Filing  
12/2/2013Clive MeanwellCEOSell10,000$36.58$365,800.00View SEC Filing  
11/26/2013Clive MeanwellCEOSell135,000$36.70$4,954,500.00View SEC Filing  
10/23/2013William Bernard O'connorSVPSell6,354$35.00$222,390.00View SEC Filing  
9/13/2013Paul Michael AntinoriVPSell73,500$34.50$2,535,750.00View SEC Filing  
9/3/2013Clive MeanwellCEOSell7,500$31.85$238,875.00View SEC Filing  
8/1/2013Clive MeanwellCEOSell7,500$31.26$234,450.00View SEC Filing  
7/8/2013Paul Michael AntinoriVPSell36,000$33.00$1,188,000.00View SEC Filing  
7/1/2013Clive MeanwellCEOSell7,500$31.25$234,375.00View SEC Filing  
6/11/2013Paul Michael AntinoriVPSell109,973$33.29$3,661,001.17View SEC Filing  
5/29/2013Armin M KesslerDirectorSell8,750$33.05$289,187.50View SEC Filing  
5/10/2013Glenn SblendorioCFOSell2,709$37.00$100,233.00View SEC Filing  
5/9/2013Paul Michael AntinoriVPSell35,000$34.90$1,221,500.00View SEC Filing  
5/9/2013William Bernard O'connorSVPSell29,654$35.00$1,037,890.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for The Medicines Company (NASDAQ:MDCO)
Latest Headlines for The Medicines Company (NASDAQ:MDCO)
DateHeadline logoSanthera's Raxone® Receives First Positive EAMS Scientific Opinion from UK's MHRA in Duchenne Muscular Dystrophy - June 22 at 2:48 AM logoThe Medicines Company (MDCO) Given Consensus Rating of "Buy" by Brokerages - June 16 at 1:08 PM logoWhy Is Alnylam (ALNY) Up 31.2% Since the Last Earnings Report? - June 8 at 10:26 AM logo$30.51 Million in Sales Expected for The Medicines Company (MDCO) This Quarter - June 4 at 8:42 AM logoThe Medicines Company (MDCO) Stock Rating Upgraded by ValuEngine - June 4 at 8:06 AM logoMedicines Co. to cut workforce as it discontinues Ionsys in the U.S. - June 2 at 7:51 PM logoMedicines Co. (MDCO) to Reduce Workforce by 15% - June 2 at 7:51 PM logoThe Medicines Company (MDCO) Expected to Announce Earnings of -$1.17 Per Share - June 2 at 2:36 PM logoThe Medicines Company to Present Data at ASM Microbe 2017 on Infectious Disease Portfolio Including Late-Stage ... - Business Wire (press release) - May 30 at 6:11 PM logoThe Medicines Company to Present Data at ASM Microbe 2017 on Infectious Disease Portfolio Including Late-Stage Investigational Antibiotic Meropenem-Vaborbactam - May 30 at 6:11 PM logoThe Medicines Company (MDCO) Expected to Earn Q3 2017 Earnings of ($1.70) Per Share - May 24 at 8:08 AM logoInvestors Purchase Large Volume of Put Options on The Medicines Company (MDCO) - May 24 at 7:08 AM logoThe Medicines Company (MDCO) Coverage Initiated at CIBC - May 23 at 2:30 PM logoResearch Analysts Offer Predictions for The Medicines Company's Q2 2017 Earnings (MDCO) - May 23 at 7:18 AM logoETFs with exposure to The Medicines Co. : May 22, 2017 - May 22 at 5:50 PM logoThe Medicines Company (MDCO) Given Average Rating of "Buy" by Analysts - May 22 at 12:25 PM logoThe Medicines Company (MDCO) Coverage Initiated at Oppenheimer Holdings Inc. - May 22 at 11:30 AM logoThe Medicines Company (MDCO) Cut to Strong Sell at ValuEngine - May 21 at 8:38 PM logoThis Fund’s Picks Gained 200% In A Year And Why No One Knows About It - May 16 at 6:17 PM logoETFs with exposure to The Medicines Co. : May 11, 2017 - May 11 at 6:58 PM logoThe Medicines Company Gets The Go-Ahead On Novel Cardiovascular Drug - May 9 at 6:11 PM logoThe Medicines Co. :MDCO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 - May 9 at 11:51 AM logoThe Medicines Company (MDCO) Expected to Announce Earnings of -$1.24 Per Share - May 9 at 8:10 AM logoDo Options Traders Know Something About Medicines Company (MDCO) Stock We Don't? - May 8 at 11:59 AM logoDo Options Traders Know Something About Medicines Company (MDCO) Stock We Don't? - May 8 at 11:59 AM logoThe Medicines Company (MDCO) Short Interest Up 3.6% in April - May 7 at 11:22 AM logoThe Medicines Company to Participate in the Bank of America Merrill Lynch 2017 Health Care Conference - Yahoo Finance - May 4 at 6:33 PM logoThe Medicines Company to Participate in the Bank of America ... - Business Wire (press release) - May 4 at 6:33 PM logoThe Medicines Company to Participate in the Bank of America Merrill Lynch 2017 Health Care Conference - May 4 at 11:42 AM logoAlnylam Teams Up With The Medicines Company To Upset PCSK9 Antibody Market - May 1 at 5:29 PM logoThe Medicines Company to Post Q2 2017 Earnings of ($1.40) Per Share, Jefferies Group Forecasts (MDCO) - May 1 at 7:55 AM logoThe Medicines Company (MDCO) Receives News Impact Score of 0.09 - April 29 at 11:33 PM logoMedicines Company (MDCO), Alnylam (ALNY) Announce Agreement with FDA on Phase III Clinical Program for Inclisiran - - April 29 at 12:25 AM logoThe Medicines Company (MDCO) Q1 Loss Wider Than Expected - Yahoo Finance - April 29 at 12:25 AM logoLeerink Swann Comments on The Medicines Company's Q2 2017 Earnings (MDCO) - April 28 at 9:40 AM logoEdited Transcript of MDCO earnings conference call or presentation 26-Apr-17 12:30pm GMT - April 27 at 7:02 PM logoThe Medicines Company (MDCO) Q1 Loss Wider Than Expected - April 27 at 9:29 AM logoBlog Coverage Medicines Co. Reaches Agreement with FDA for the Phase III Trial for Inclisiran - April 27 at 9:28 AM logoThe Medicines (MDCO) Q1 2017 Results - Earnings Call Transcript - April 26 at 6:53 PM logoMedicines Company (MDCO), Alnylam (ALNY) Announce Agreement with FDA on Phase III Clinical Program for Inclisiran - April 26 at 6:53 PM logoThe Medicines Company Reports First-Quarter 2017 Financial Results - April 26 at 6:53 PM logoMedicines Co. reports 1Q loss - April 26 at 6:53 PM logoThe Medicines Co. – Value Analysis (NASDAQ:MDCO) : April 26, 2017 - April 26 at 6:53 PM logoThe Medicines Company (MDCO) Releases Earnings Results, Misses Expectations By $0.21 EPS - April 26 at 6:30 PM logoThe Medicines reports Q1 results - April 26 at 10:28 AM logoMedicines beats by $0.22, misses on revenue - April 26 at 7:23 AM logoThe Medicines Co. breached its 50 day moving average in a Bearish Manner : MDCO-US : April 25, 2017 - April 25 at 5:48 PM logoThe Medicines Company (MDCO) Receives Consensus Rating of "Buy" from Brokerages - April 25 at 12:33 PM logoDrug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More - April 25 at 8:33 AM logoEditas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting - April 24 at 3:27 PM



The Medicines Company (MDCO) Chart for Thursday, June, 22, 2017

This page was last updated on 6/22/2017 by Staff